Bristol-Myers Squibb Company

BMY · NYSE · USD

PoliticiansInstitutionalInsiders

Current holders

Politician	Disclosed
Donald Trump R · EXECUTIVE	net $98K – $528K 12 disclosures · 9 bought / 3 sold · last Jun 23, 2026
Kurt Schrader D · HOUSE · OR	$101K – $265K $78K – $204K today 2 filings · last Nov 8, 2022
Ro Khanna D · HOUSE · CA	−$656K – $767K −$762K – $858K today 68 filings · last Jun 16, 2026
John A. Yarmuth D · HOUSE · KY	−$11K – $59K −$13K – $63K today 5 filings · last Sep 23, 2021
Thomas R. Carper D · HOUSE · DE	$3K – $45K $3K – $46K today 3 filings · last Jan 18, 2022
Thomas R. Suozzi D · HOUSE · NY	−$109K – $130K −$129K – $122K today 10 filings · last Jun 7, 2021
Kathy E. Manning D · HOUSE · NC	$1K – $15K $814 – $12K today 1 filing · last Jul 15, 2022
Val T. Hoyle D · HOUSE · OR	$1K – $15K $1K – $18K today 1 filing · last Oct 29, 2024
Diana Harshbarger R · HOUSE · TN	$1K – $15K $841 – $13K today 1 filing · last Jan 25, 2023
Alan Armstrong R · SENATE · OK	$1K – $15K $1K – $16K today 1 filing · last Mar 27, 2026

Recent transactions

Trades from Mar 27, 2025 – Jun 23, 2026

Politician	Type	Filed after	Amount
Donald Trump R · EXECUTIVE	Sell	60 days Jun 23, 2026 → Aug 22, 2026	≥$1K
Donald Trump R · EXECUTIVE	Buy	71 days Jun 12, 2026 → Aug 22, 2026	≥$15K
Alan Armstrong R · SENATE · OK	Buy	116 days Mar 27, 2026 → Jul 21, 2026	≥$1K
Ro Khanna D · HOUSE · CA-17	Sell	20 days Jun 16, 2026 → Jul 6, 2026	≥$1K
Donald Trump R · EXECUTIVE	Buy	44 days May 18, 2026 → Jul 1, 2026	≥$1K
Donald Trump R · EXECUTIVE	Sell	44 days May 18, 2026 → Jul 1, 2026	≥$1K
Donald Trump R · EXECUTIVE	Buy	47 days May 15, 2026 → Jul 1, 2026	≥$15K
Donald Trump R · EXECUTIVE	Sell	51 days May 11, 2026 → Jul 1, 2026	≥$15K
Mike Kelly R · HOUSE · PA-16	Sell	35 days May 7, 2026 → Jun 11, 2026	≥$15K
Ro Khanna D · HOUSE · CA-17	Buy	25 days May 15, 2026 → Jun 9, 2026	≥$1K

Congressional trading data provided by QuiverQuant

Institutional

Investors holding

2,625

13F shares

1.74B

Total invested

$101B

Ownership

85.4%

New positions

179

Closed positions

198

Increased positions

1,182

Reduced positions

1,016

Put/Call ratio

0.89

Holder	Reported	Shares	Value	Δ Qtr
BLACKROCK, INC.	8/7/2026	180.4M	$10.4B	+5.07%
VANGUARD CAPITAL MANAGEMENT LLC	8/13/2026	133.3M	$7.7B	+0.77%
STATE STREET CORP	9/22/2026	102.4M	$5.9B	+3.90%
JPMORGAN CHASE & CO	8/12/2026	71.7M	$4.2B	−22.45%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	8/14/2026	67.6M	$3.9B	+10.60%
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P.	8/14/2026	67.6M	$3.9B	—
GEODE CAPITAL MANAGEMENT, LLC	8/12/2026	56.4M	$3.2B	+2.09%
VANGUARD PORTFOLIO MANAGEMENT LLC	8/13/2026	46.9M	$2.7B	+1.39%
NORGES BANK	8/12/2026	36.9M	$2.1B	—
BANK OF AMERICA CORP /DE/	8/14/2026	34M	$2.0B	+4.48%
PRICE T ROWE ASSOCIATES INC /MD/	8/14/2026	31.7M	$1.8B	+209.34%
MORGAN STANLEY	8/13/2026	29M	$1.7B	−0.65%
AQR CAPITAL MANAGEMENT LLC	8/14/2026	27.4M	$1.6B	−7.67%
AMERIPRISE FINANCIAL INC	8/14/2026	26.7M	$1.5B	+0.75%
PRIMECAP MANAGEMENT CO/CA/	8/14/2026	24.9M	$1.4B	−0.25%
NORTHERN TRUST CORP	8/13/2026	24.9M	$1.4B	+0.64%
UBS ASSET MANAGEMENT AMERICAS INC	8/13/2026	22.8M	$1.3B	+0.53%
BANK OF NEW YORK MELLON CORP	8/6/2026	21.8M	$1.3B	−6.35%
INDEPENDENT FRANCHISE PARTNERS LLP	8/13/2026	21.8M	$1.3B	+2.43%
DIMENSIONAL FUND ADVISORS LP	8/11/2026	19.7M	$1.1B	+4.95%
LEGAL & GENERAL GROUP PLC	8/14/2026	17M	$980.9M	+0.86%
GOLDMAN SACHS GROUP INC	8/14/2026	17M	$980.5M	+21.08%
PZENA INVESTMENT MANAGEMENT LLC	8/7/2026	17M	$979.9M	−0.52%
FMR LLC	8/13/2026	16.3M	$938.8M	+52.69%
INVESCO LTD.	8/14/2026	16M	$923.8M	+3.38%

Insider transactions

Insider	Type	Transacted	Price	Date
Samuels Theodore R. Ii	A-AWARD	821	—	Sep 30
McMullen Michael R.	A-AWARD	561	—	Sep 30
Rice Derica W	A-AWARD	621	—	Sep 30
Arduini Peter J	A-AWARD	561	—	Sep 30
Yale Phyllis R	A-AWARD	561	—	Sep 30
Massacesi Cristian	S-SALE	6.2K	$64.57	Sep 9
Short Bartie Wendy	M-EXEMPT	1.2K	—	Sep 1
Short Bartie Wendy	M-EXEMPT	1.2K	$66.92	Sep 1
Short Bartie Wendy	F-INKIND	633	$66.92	Sep 1
Holzer Phil M	S-SALE	500	$67.50	Aug 25

Analyst consensus

Hold42 analysts

Bearish · 2 · Hold · 21 · Bullish · 19

Earnings history

	EPS	Estimate
Q3 2024	$1.80	$1.49	Beat
Q4 2024	$1.67	$1.47	Beat
Q1 2025	$1.80	$1.49	Beat
Q2 2025	$1.46	$1.09	Beat
Q3 2025	$1.63	$1.52	Beat
Q4 2025	$1.26	$1.23	Beat
Q1 2026	$1.58	$1.42	Beat
Q2 2026	$2.04	$1.60	Beat

Peers

Company overview

IPO dateJun 1, 1972

CEOChristopher Boerner

Employees32,500

SectorHealthcare

IndustryDrug Manufacturers - General

CountryUS

ExchangeNew York Stock Exchange

Websitewww.bms.com

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.